

Datasheet: HCA213

Description:	HUMAN ANTI INFLIXIMAB
Specificity:	INFLIXIMAB
Other names:	REMICADE
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD17841_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line.
---------------------	--

Preparation	Purified IgG prepared by affinity chromatography on Protein A
--------------------	---

Buffer Solution	Phosphate buffered saline
------------------------	---------------------------

Preservative Stabilisers	0.01% Thiomersal
---------------------------------	------------------

Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
---------------------------------------	----------------------------------

Immunogen	Infliximab
------------------	------------

Specificity

Human Anti-Infliximab, clone AbD17841_hlgG1 is an anti-idiotypic antibody that specifically recognizes the infliximab monoclonal antibody and inhibits the binding of infliximab to its target. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

Human anti Infliximab, clone AbD17841_hlgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD17841_IgG1 is suitable as a detection

antibody in pharmacokinetic (PK) assays.

Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

Infliximab is directed against Tumor Necrosis Factor Alpha (TNF α) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNF α expressing T-lymphocytes.

[View a summary of all Anti-Infliximab Antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=1.8$ nM by real time, label-free molecular interaction analysis on immobilized Infliximab.
ELISA	This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 as the capture reagent. Protocol: PK bridging ELISA to measure free drug Protocol: ADA bridging ELISA
References	<ol style="list-style-type: none">Hernández-Breijo, B. <i>et al.</i> (2015) Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator. 10th Congress of ECCO, Barcelona P020Hernández-Breijo, B. <i>et al.</i> (2016) Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab. Biochem Pharmacol. Sep 21. pii: S0006-2952(16)30302-1. [Epub ahead of print]
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[RECOMBINANT HUMAN TNF ALPHA \(PHP051\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA212\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA214\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA215\)](#)

[HUMAN ANTI INFLIXIMAB \(HCA216\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

'M371634:200612'

Printed on 14 Sep 2020